

# <Manuscript Submission Guidelines>

## Yakhak Hoeji

(The Journal of Pharmaceutical Society of Korea)

### 1. Aims and Scope

Yakhak Hoeji is an official domestic journal of the Pharmaceutical Society of Korea and has been published since 1948. Yakhak Hoeji is a peer-reviewed journal devoted to all areas of pharmaceutical sciences including basic, translational, clinical, and pharmacy-related social studies. This journal aims to represent the academic output on pharmaceutical sciences and pharmacy practice to build an academic exchange platform among pharmaceutical scientists, researchers, and pharmacists so that the readers could update the recent scientific knowledge and academic trends, ultimately leading to further development on the pharmaceutical sciences.

Manuscripts will be considered for publication on the condition that the results reported are based on research works that has not been published elsewhere in any journal.

### 2. Eligibility

Author (at least one author in case of multiple authors) of submitted manuscript must be a member. Non-members can submit their manuscript upon the approval of the editorial board.

### 3. Copyright

When the manuscript is submitted, authors will be asked to transfer copyright of the article by submitting its form to the Publisher. The copyright of published manuscript is held by the Pharmaceutical Society of Korea.

### 4. Manuscript language

Yakhak Hoeji (The Journal of Pharmaceutical Society of Korea) must be written in Korean or English language.

Manuscripts should be prepared as follows:

Abstract: English language

Text: Korean or English

Figure, Table: English

References: English

### 5. Manuscript types and format

The Pharmaceutical Society of Korea publishes original research articles, short reports, continued reports and review articles.

Authors should not submit a manuscript that has been previously published or being reviewed simultaneously elsewhere at home or abroad.

Original research articles and short reports should include an Abstract in English.

#### 5.1. Original research articles

Original research articles must contain substantial novel findings obtained from a creative study.

##### (1) Manuscript length

There is no limit on the length of a manuscript, but the content of manuscript must be clear to understand and avoid wordiness.

##### (2) Manuscript format

Manuscripts should include the following sections in the order listed: Abstract, Introduction, Methods, Results and Discussion, Conclusion, Acknowledgment, Conflict of Interest, References. In addition, results and discussion could be separately described.

#### 5.2. Short reports

Short reports must contain novel findings or valuable data.

##### (1) Manuscript length

The length of short reports should not exceed three pages when printed. There can be an exception upon the approval of the editorial board. However, the manuscript should not exceed 2,600 words, including figures and tables.

##### (2) Manuscript format

The standard format required for original research articles is recommended, but combining multiple sections into one section is allowed.

#### 5.3. Continued reports

Continued reports must contain novel experimental results in need of urgent disclosure. Any reason for the need for urgent publication should be stated separately in text.

##### (1) Manuscript length

The length of short reports should not exceed two pages when printed. There can be an exception upon the approval of the editorial board.

##### (2) Manuscript format

The standard formatting is not required for clinical experiments.

#### 5.4. Review articles

Review articles should contain the review of the latest studies results and measurement data published at home or abroad.

### 6. Manuscript format

Articles must be written in a format set by the Pharmaceutical Society of Korea.

## 7. Manuscript submission

Manuscripts must be submitted online ([www.yakhak.org](http://www.yakhak.org)).

All manuscripts must be typed on A4 paper using MS-Word or Hangul.

## 8. Review process

(1) All manuscripts are evaluated by at least two independent reviewers and the review results will be classified into the following four categories:

- a. Accept
- b. Minor revision
- c. Major revision
- d. Reject

(2) If the revised version of manuscript is not received within 2 months after notice, we assume the manuscript has been withdrawn.

## 9. Manuscript edition

(1) Authors are fully responsible for editions of their manuscripts.

(2) Authors can edit their manuscript that is peer-reviewed, if they want.

(3) But they should not revise content or add new content on their own. If peer-reviewed manuscript is re-edited for changes or new content, it is subject to re-review of the editorial board. And its author is responsible for paying any expenses incurred by the re-review. If the submission of revised manuscript is delayed beyond deadline, authors can postpone the publication.

## 10. Correction

(1) Authors are required to submit their corrections to us after publication, if they need to make any corrections to their articles that have been published.

(2) Their corrections will be published after reviewing by

the editorial board.

## 11. Charges to authors

(1) Authors are required to pay KRW 50,000 for submission fee and KRW 20,000 per page of their manuscript published. In addition, the invited manuscripts can be waived for the charges to authors.

(2) Authors will receive a pdf file of their article.

## 12. Research and publication ethics

For the policies on the research and publication ethics not stated in this instructions, International standards for editors and authors (<https://publicationethics.org/resources/international-standards-for-editors-and-authors>) can be applied.

*Process for Managing Research and Publication Misconduct* : When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author's idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (<http://publicationethics.org/resources/flowcharts>). The discussion and decision on the suspected cases are carried out by the Editorial Board.

## Additional clauses

1. These manuscript submission guidelines took effect January 1, 2021.

2. These manuscript submission guidelines are revised by the editorial board at December 28, 2020.

# Editorial Requirements for Manuscripts submitted to Yakhak Hoeji (The Journal of Pharmaceutical Society of Korea)

Established October 1965  
1<sup>st</sup> ed. December 1970  
2<sup>nd</sup> ed. December 1972  
3<sup>rd</sup> ed. January 1986  
4<sup>th</sup> ed. September 1995  
5<sup>th</sup> ed. March 2017  
6<sup>th</sup> ed. December 2017  
7<sup>th</sup> ed. December 2020

1. These editorial requirements are aimed to provide uniform standards to be used by authors for the preparation of their manuscripts, based on Article 5 of the Manuscript Submission Guidelines.

2. Each section should start on a new page using the following terms in the following order:

## 1. Cover page

The cover page must contain title, author name, institution, and contact details of the corresponding author (telephone, fax, email, abbreviated title, and institutional address in the order listed). All of this information must be written in Korean, followed by English version in the same order.

### 1.1. Title

a. Title should be clear and concise to reflect the content of manuscript. Do not include descriptions such as “the study on ...”, if possible.

b. The title should not include any abbreviation and molecular formula except for isotope or labeled compounds. A scientific name can be used without the name of author.

c. Title should be fully presented in Korean and in English. Korean title should be presented in reference with the Scientific & Technical Terminology Dictionary or Pharmaceutical Terminology.

### 1.2. Author names

When multiple authors are involved and their institution and address are different, place 「\*」 at the end of the first author name as a subscript and place 「\*\*」 at the end of the second author name and so on.

Capitalize the first character of each syllable in author name in English. The last author's name should be preceded by “and” while the other authors' names should be followed by “,”. When only two authors are involved, the names should be separated by “and”.

### 1.3. Institution and address

All institutions and their address (including zip code) should be written in Italics. When there are multiple institu-

tions, place 「\*」 or 「\*\*」 at the end of institution name that corresponds to each author. When the current address differs from the institutional address where research took place, the latter should be presented first and followed by the former in the next line.

## 1.4. Abbreviated title

Abbreviated title should be presented in Korean or in English on lower right side of the page. This title should be concise and easy to understand.

## 2. Abstract

The abstract must be written in English with approximately 200 words featuring the overview of the study objectives and results. The abstract must be written as a paragraph and it should not refer to graphs within the text.

## 3. Introduction

The main purpose of the study and results achieved in the study should be described in a brief and concise style.

## 4. Methods

The description must be detailed to allow replication. New methods and protocols should be described in detail whereas the description of previously published methods should include the underlying principle briefly and its source.

## 5. Results and Discussion

Experimental results should be described, and interpretation and discussion of those results can be presented.

Authors can separate Results and Discussion section, but in this case, duplicate description of contents should be avoided.

The results of experiments presented in figures should not repeat data described in tables or vice versa.

## 6. Conclusion

Conclusion should be clear to understand. Authors can combine the Conclusion and Discussion.

## 7. Acknowledgements

At the end of the manuscript, Acknowledgements should appear with the statement part. All sources of funding of the study should be disclosed.

## 8. Conflict of Interest

When articles are submitted for consideration for publication, authors must indicate all sources of funding for the submitted work along with any potential financial or other interests that may be perceived to bias the research. This includes departmental, governmental, public interest, or institutional funds. All sponsors must be identified, even if their support is indirect. Authors are not required to state the monetary value of their financial interests. Even if there are no conflict of interest, this should be stated in the Conflict of Interest section.

E.g.) All authors declare that they have no conflict of interest.

E.g.) James Baker has received research grants from Drug Company A.

## 9. References

(1) All references should be arranged in numerical order according to the sequence of citations in the text.

E.g.) Han *et al.*<sup>1)</sup>

If a reference is cited more than once in the text, the first number from the sequence is used as the reference number.

(2) Unpublished papers or letters should only be mentioned in the text and not be listed as references.

(3) Any abbreviations used in references should conform to ISSN List of Title Word Abbreviations ([www.issn.org/2-22661-LTWA-online.php](http://www.issn.org/2-22661-LTWA-online.php)). When abbreviation is not certain or when making references to books, full name should be used.

(4) All author names should be described in the reference list and article title should be also included.

(5) Other requirements for reference listing are as follows:  
Journal article)

Elemdorf DF, Cawthon WV, Muschenheim C, McDermott W (1952) The absorption, distribution, excretion and short time toxicity of isonicotinic acid hydrazide (Nydrazide) in man. *Am Rev Tuber* 65: 429-442.

Book)

Moynihan H, Crean A (2009) *The physicochemical basis of pharmaceuticals*. Oxford University Press Inc., New York.

Book chapter)

Na DH, Lee KC (2007) Capillary separation techniques. In: Gad SC (ed) *Handbook of pharmaceutical biotechnology*, John Wiley & Sons, Inc., New Jersey, pp 469-510.

Online document)

Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. <http://physicsweb.org/articles/news/11/6/16/1>. Accessed 26 June 2007.

Dissertation)

Trent JW (1975) *Experimental acute renal failure*. Dissertation, University of California.

## 10. Figure, Table, and Scheme

(1) All explanatory captions must be written in English.

(2) Each figure, table and scheme should start on a new page, and explanatory caption for figures and schemes should be collected on a separate page at the end of the section.

(3) All figures will be printed in width of 7.5 cm in most cases. So the size of letters and numerals should be aligned with the photo size.

Symbols can be used in the following order: ●, ○, ×, ■, ▲, □, △. Each symbol should be defined in explanatory caption.

(4) Each table can be created using two transversal lines. Explanation of tables should appear below the table. Vertical lines should not be used to separate columns, if possible.

## 11. Names of materials, numbers, symbols, etc

(1) **Names of materials:** Names of materials should conform to those defined by either the Korean Pharmacopoeia or International Union of Pure and Applied Chemistry (IUPAC), depending on language. Material names should not be capitalized with the exception of abbreviations. The use of brand names is not recommended but the first character should be capitalized in evitable cases.

(2) **Numbers:** Arabic numerals should be used.

(3) **Symbols:** Symbols and signs should conform to those defined by SI or conventional symbols and signs commonly used in International Context.

### Additional clauses

1. These editorial requirements for manuscripts took effect 1/1/2021.

2. These requirements are revised by the editorial board.

3. Any topics not covered in these requirements are subject to structure or style of the latest edition of the Journal of Pharmaceutical Society of Korea.